Biocon Publishes Pivotal Clinical Data for Yesafili Ahead of US Launch

Biocon Limited has published pivotal Phase III clinical data for its aflibercept biosimilar, Yesafili (MYL-1701P), in two major medical journals. The findings reinforce the drug's safety and efficacy profile ahead of its highly anticipated commercial launch in the United States. Key Clinical Highlights: Proven Equivalence: Data from the Phase III INSIGHT trial and its 20-week extension demonstrate that MYL-1701P delivers visual acuity and retinal thickness outcomes comparable to the reference drug, Eylea (aflibercept). Safety Profile: The studies confirm similar safety, efficacy, and immunogenicity outcomes across diverse patient subgroups, with no new safety signals identified. Regulatory & Commercial Context: FDA Status: Yesafili received US FDA approval and a highly coveted "interchangeable" designation in May 2024, allowing it to be substituted for the reference product at the pharmacy level. Key Indications: The drug is indicated for treating Neovascular (Wet) Age-Related Macular Degeneration, Diabetic Macular Edema (DME), Diabetic Retinopathy, and Macular Edema following Retinal Vein Occlusion. Strategic Impact: The publication of this robust clinical dataset significantly strengthens the evidence base for Yesafili. By validating its clinical equivalence to Eylea, Biocon is well-positioned to capture substantial market share in the lucrative US ophthalmology biosimilars sector upon launch.